# EDGAR Filing Document

**Accession Number:** 0001231457
**File Stem:** 9999999997-23-000334
**Filing Date:** 2023-1
**Character Count:** 1678
**Document Hash:** 2bddeb1ccfc0082ebe91007c65250db0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**9999999997-23-000334.hdr.sgml**: 20230223

**ACCESSION NUMBER**: 9999999997-23-000334

**CONFORMED SUBMISSION TYPE**: SEC STAFF LETTER

**CATEGORY**: REDACTED EXHIBIT

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230126

**ACTION DATE**: 20230126

**RECEIVED DATE**: 20230127

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GENELUX CORP
- **CENTRAL INDEX KEY:** 0001231457
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SEC STAFF LETTER

**BUSINESS ADDRESS:**
- **STREET 1:** 1177 IDAHO STREET
- **CITY:** REDLANDS
- **STATE:** CA
- **ZIP:** 92374
- **BUSINESS PHONE:** 858-483-0024

**MAIL ADDRESS:**
- **STREET 1:** 1177 IDAHO STREET
- **CITY:** REDLANDS
- **STATE:** CA
- **ZIP:** 92374

### Attached PDF Documents

**Attachment 1:** `filename1`

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

January 26, 2023

Thomas Zindrick, J.D.
President and Chief Executive Officer
Genelux Corporation
2625 Townsgate Road, Suite 230
Westlake Village, California 91361

**Re: Genelux Corporation**
**Amendment No. 1 to Registration Statement on Form S-1**
**Exhibit Nos. 10.16, 10.17, 10.18 and 10.19**
**Filed August 29, 2022**
**File No. 333-265828**

Dear Mr. Zindrick:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance